CD4+T Cells Targeting Dominant and Cryptic Epitopes from <em>Bacillus anthracis</em> Lethal Factor by Ascough S et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This work is licensed under a Creative Commons Attribution 4.0 International License 
 
 
Newcastle University ePrints - eprint.ncl.ac.uk 
 
 
 
Ascough S, Ingram RJ, Chu KKY, Musson JA, Moore SJ, Gallagher T, Baillie L, 
Williamson ED, Robinson JH, Maillere B, Boyton RJ, Altmann DM.  
CD4+T Cells Targeting Dominant and Cryptic Epitopes from Bacillus anthracis 
Lethal Factor.  
Frontiers in Microbiology 2016, 6, 1506. 
 
Copyright: 
© 2016 Ascough, Ingram, Chu, Musson, Moore, Gallagher, Baillie, Williamson, Robinson, Maillere, 
Boyton and Altmann. This is an open-access article distributed under the terms of the Creative 
Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is 
permitted, provided the original author(s) or licensor are credited and that the original publication in 
this journal is cited, in accordance with accepted academic practice. No use, distribution or 
reproduction is permitted which does not comply with these terms. 
DOI link to article: 
http://dx.doi.org/10.3389/fmicb.2015.01506  
Date deposited:   
05/04/2016 
ORIGINAL RESEARCH
published: 05 January 2016
doi: 10.3389/fmicb.2015.01506
Edited by:
Tao Dong,
University of Oxford, UK
Reviewed by:
Kirsten McCabe,
Los Alamos National Laboratory, USA
Ram P. Kamal,
Centers for Disease Control
and Prevention, USA
*Correspondence:
Daniel M. Altmann
d.altmann@imperial.ac.uk
Specialty section:
This article was submitted to
Infectious Diseases,
a section of the journal
Frontiers in Microbiology
Received: 07 September 2015
Accepted: 14 December 2015
Published: 05 January 2016
Citation:
Ascough S, Ingram RJ, Chu KKY,
Musson JA, Moore SJ, Gallagher T,
Baillie L, Williamson ED, Robinson JH,
Maillere B, Boyton RJ
and Altmann DM (2016) CD4+ T Cells
Targeting Dominant and Cryptic
Epitopes from Bacillus anthracis
Lethal Factor.
Front. Microbiol. 6:1506.
doi: 10.3389/fmicb.2015.01506
CD4+ T Cells Targeting Dominant
and Cryptic Epitopes from Bacillus
anthracis Lethal Factor
Stephanie Ascough1, Rebecca J. Ingram2, Karen K. Y. Chu3, Julie A. Musson4,
Stephen J. Moore5, Theresa Gallagher5, Les Baillie6, Ethel D. Williamson7,
John H. Robinson4, Bernard Maillere8, Rosemary J. Boyton3 and Daniel M. Altmann3*
1 Avian Viral Immunology Group, The Pirbright Institute, Pirbright, UK, 2 Centre for Infection and Immunity, Queen’s University
Belfast, Belfast UK, 3 Section of Infectious Diseases and Immunity, Department of Medicine, Imperial College London,
London, UK, 4 Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK, 5 Center for Biomedical
Engineering and Technology, University of Maryland School of Medicine, Baltimore, MD, USA, 6 School of Pharmacy and
Pharmaceutical Sciences, Cardiff University, Cardiff, UK, 7 Defence Science and Technology Laboratory, Salisbury, UK,
8 Service d’Ingénierie Moléculaire des Protéines, Insititut de Biologie et de Technologies de Saclay, Commiseriat à l’Energie
Atomique, Gif Sur Yvette, France
Anthrax is an endemic infection in many countries, particularly in the developing world.
The causative agent, Bacillus anthracis, mediates disease through the secretion of
binary exotoxins. Until recently, research into adaptive immunity targeting this bacterial
pathogen has largely focused on the humoral response to these toxins. There is,
however, growing recognition that cellular immune responses involving IFNγ producing
CD4+ T cells also contribute significantly to a protective memory response. An
established concept in adaptive immunity to infection is that during infection of host
cells, new microbial epitopes may be revealed, leading to immune recognition of so
called ‘cryptic’ or ‘subdominant’ epitopes. We analyzed the response to both cryptic
and immunodominant T cell epitopes derived from the toxin component lethal factor and
presented by a range of HLA-DR alleles. Using IFNγ-ELISpot assays we characterized
epitopes that elicited a response following immunization with synthetic peptide and the
whole protein and tested their capacities to bind purified HLA-DR molecules in vitro.
We found that DR1 transgenics demonstrated T cell responses to a greater number
of domain III cryptic epitopes than other HLA-DR transgenics, and that this pattern
was repeated with the immunodominant epitopes, as a greater proportion of these
epitopes induced a T cell response when presented within the context of the whole
protein. Immunodominant epitopes LF457 476 and LF− 467−487 were found to induce a
T cell response to the peptide, as well as to the whole native LF protein in DR1 and
DR15, but not in DR4 transgenics. The analysis of Domain I revealed the presence
of several unique cryptic epitopes all of which showed a strong to moderate relative
binding affinity to HLA-DR4molecules. However, none of the cryptic epitopes from either
domain III or I displayed notably high binding affinities across all HLA-DR alleles assayed.
These responses were influenced by the specific HLA alleles presenting the peptide,
and imply that construction of future epitope string vaccines which are immunogenic
across a wide range of HLA alleles could benefit from a combination of both cryptic and
immunodominant anthrax epitopes.
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INTRODUCTION
The acute zoonotic disease, anthrax, caused by the Gram-positive
bacterium Bacillus anthracis, is endemic or hyperendemic in
a number of regions, particularly developing countries in
sub-Saharan Africa, South America, and Asia (Dixon et al.,
1999). The disease primarily affects grazing animals, with
sporadic outbreaks in humans usually confined to agricultural
workers and individuals in contact with the skins and fibers
of infected animals (Wattiau et al., 2009). Anthrax has
historically garnered attention because of its efficacy as a
bioweapon, due to a high case fatality rate, limited person-
to-person spread and the formation of spores that can be
stockpiled in a weaponized form for prolonged periods. This was
demonstrated in 2001, when anthrax spores were deliberately
disseminated in the United States mail, resulting in a total
of 22 cases of anthrax, with a 45% fatality rate in patients
with inhalational disease, despite appropriate antibiotic therapy
(Jernigan et al., 2002). More recently, anthrax outbreaks have
been reported in persons who inject drugs (PWIDs) in Northern
Europe during 2009–2010 and 2012–2013 (Ramsay et al.,
2010; Ascough et al., 2014a; Berger et al., 2014; Ascough and
Altmann, 2015). These cases involved the injection of heroin,
contaminated with anthrax spores, directly into subcutaneous
tissue. It is currently believed that a single B. anthracis strain
type, closely related to strains from Turkey, was responsible
for the outbreaks, and may have been introduced through
contact with animal skins used to smuggle the heroin into
Europe (Price et al., 2012; Grunow et al., 2013). These cases
have illustrated that anthrax still remains an environmental
hazard in many parts of the developing world, capable of
impacting upon the health of people over a wide geographic
range.
The main virulence factors of B. anthracis are encoded by
genes found on two large plasmids. The structural genes which
code for toxin production are carried on the 184.5 kbp plasmid,
pXO1 and the formation of a poly-γ-D-glutamic acid capsule
is directed by genes found on the 95.3 kbp plasmid, pXO2
(Duesbery and Vande Woude, 1999). Three of the genes found
on pXO1; pagA, lef and cya, are responsible for encoding
the three toxins associated with pathogenicity of B. anthracis;
Protective Antigen (PA), Lethal Factor (LF) and Edema Factor
(EF), respectively. The PA protein binds to either EF or LF to
form the binary exotoxins Edema Toxin (ET), or Lethal Toxin
(LT; Liu et al., 2014). Through binding to cell surface receptors,
these toxins are endocytosed into the cytoplasm, where they
affect the survival and multiplication of the bacilli within the
host, subverting host immunity (Duesbery and Vande Woude,
1999).
The current licensed human vaccines, anthrax vaccine
precipitated (AVP) and anthrax vaccine adsorbed (AVA or
Biothrax), are both comprised of filtered supernatants from
cell cultures of pXO1+/pXO2– B. anthracis strains, containing
variable concentrations of the anthrax toxins (Williamson and
Dyson, 2015). Ongoing efforts to develop more rigorously
defined ‘next generation’ vaccines demand the characterisation
of immune responses to potential antigens (Altmann, 2015).
Despite the preponderance of studies that focus on the
importance of PA in developing vaccination strategies against
anthrax infection, it has lately become clear that LFmay represent
a major target not only for antibody responses, but also T
cell immunity in naturally exposed individuals. Our previous
work has shown that epitopes identified from domains II and
IV of LF dominate a Th1 associated IFNγ response, and are
presented to CD4+ cells in the context of a broad range
of HLA DR molecules (Ingram et al., 2010; Ascough et al.,
2014b).
Antigens, such as the mature secreted LF protein, which
is composed of 776 amino acid residues, typically possess a
large number of possible immunogenic peptide sequences, but
the cellular immune response focuses on a relatively restricted
number of determinants, which contribute to the development
of a T cell response against epitopes processed from the
whole protein antigen. Epitopes capable of triggering this kind
of potent T cell response, following in vivo priming with
either the whole protein or peptide antigens, are classified
as immunodominant. In contrast, epitopes that are normally
hidden from T-cell recognition, but are immunogenic in
peptide form, are termed cryptic or subdominant epitopes.
Initial studies of this phenomenon concentrated on model
antigens such as hen egg lysozyme (Maizels et al., 1980;
Adorini et al., 1988a,b; Nelson et al., 1992; Sercarz et al.,
1993; Viner et al., 1995), the most intensive study of cryptic
epitopes in disease has been carried out within the context
of determinant spreading in autoimmunity, during which
autoreactive T cell epitope recognition expands from a limited
number of immunodominant epitopes to numerous cryptic
epitopes (Lehmann et al., 1992; Sercarz, 1998; Vanderlugt
and Miller, 2002; McMahon et al., 2005; Ji et al., 2013).
However, recent work has suggested that the incorporation
of subdominant or cryptic epitopes into vaccines, alongside
immunodominant T cell epitopes, may have a major advantage
in aiding the development of an immune response against
microbial pathogens (Dominguez et al., 2011). The T cell
repertoire of the immune response following immunization and
infection has proven to differ in regard to immunodominant
epitopes, and our own studies in humans have demonstrated
that exposure to live B. anthracis bacteria uncovers epitopes
within LF, which were not identified as T cell determinants
following protein antigen vaccination (Ingram et al., 2010).
This suggests that crypticity status of epitopes varies between
exposure to living pathogens and protein vaccination, so
that such responses can come to play an essential role
in directing the immune response to pathogens in vivo.
Dominguez et al. (2011) found that immunization with cryptic
and subdominant determinants from the protozoan parasite
Trypanosoma cruzi contribute to an artificially broadened CD8+
repertoire that provides increased protection against infection,
compared to immunization with the single immunodominant
epitope. Woodworth et al. (2014) demonstrated the ability of
cryptic epitope specific T cells to resist lymphocyte terminal
differentiation during Mycobacterium tuberculosis infection,
maintaining polyfunctionality and enhanced antigen specific
proliferation. There is evidence that CD4+ T cells directed against
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cryptic epitopes provide enhanced protection against pathogen
challenge (Aagaard et al., 2009), it is therefore conceivable that
polyepitopic vaccines, containing both cryptic or subdominant
and immunodominant epitopes, may act to broaden the peptide
specificity of T cells, reducing the ability of pathogens to escape
recognition by the immune system. Analysis of the antigen
specific T cell response to LF, and identification of a range
of immunogenic epitopes for incorporation into an epitope
string vaccine may represent a more successful vaccination
strategy.
MATERIALS AND METHODS
HLA Transgenic Mice
HLA class II transgenic mice carrying genomic
constructs for HLA products common in the human
population; HLA-DRA1∗0101/HLA-DRB1∗0101 (HLA-DR1),
HLA-DRA1∗0101/HLA-DRB1∗0401 (HLA-DR4), and HLA-
DRA1∗0101/HLA-DRB1∗1501 (HLA-DR15) were crossed for
more than six generations to C57BL/6 H2-Aβ00 mice, leading
to lines lacking endogenous MHC class II molecules, these
mice were generated and maintained as described previously
(Ascough et al., 2014b).
Research was conducted in compliance with the Animals
(Scientific Procedures) Act 1986 and UK legislation relating to
experiments involving animals. All experiments were approved
by local ethical review and the facility where this research was
conducted was licensed by the Home Office.
LF Antigens
A biologically inactive form of recombinant full-length LF
(rLF) was produced in an Escherichia coli expression system as
previously described (Baillie et al., 2004). A synthetic peptide
panel, comprising of 20mer amino acids overlapping by 10 amino
acids encompassing the full-length sequence of LF was purchased
from Abgent, San Diego, CA, USA.
LF Epitope Mapping
HLA transgenic mice were immunized subcutaneously with
either individual immunodominant epitopes, or pools of non-
overlapping LF peptides comprising domains III or I, (each pool
containing ≤6 peptides) emulsified in Titermax Gold adjuvant
(Sigma–Aldrich, USA). After 10 days, local draining popliteal
lymph nodes were removed and disaggregated into single cell
suspensions. Lymph node cells (3.5 × 106/ml) were challenged
with 25 μg/ml of either recombinant full-length LF, or individual
LF peptides.
IFNγ ELISpot Assays
Antigen-specific IFNγ levels from ex vivo murine T cell
populations were analyzed by ELISpot (Diaclone), as previously
described (Ascough et al., 2014b). In brief, ethanol pre-wetted
hydrophobic PVDF membrane-bottomed 96-well plates (MAIP
S 45; Millipore) were washed twice with PBS, then coated with
anti-IFNγ monoclonal antibody at 4◦C overnight. Plates were
blocked with 2% skimmed milk, washed twice with PBS, and
100μl/well of antigenwas added in triplicate. Each assay included
a medium only negative and a positive control of SEB (25 ng/ml).
Wells were seeded with 100 μl of 3.5 × 106cells/ml in HL-
1 medium (1% L-Glutamine, 1% Penicillin Streptomycin, 2.5%
β-Mercaptoethanol). Following incubation for 72 h at 37◦C with
5% CO2, plates were washed twice with PBS Tween 20 (0.1%).
Plates were incubated with biotinylated anti-IFNγ monoclonal
antibody, then washed with PBS Tween 20 (0.1%). Incubation
with streptavidin-alkaline phosphatase conjugate was followed
by PBS Tween 20 (0.1%) washes and then treated with 5-
bromo-4-chloro-3-indolyl phosphate and nitroblue tetrazolium
(BCIP/NBT). Spot formation was monitored visually and plate
contents were discarded. After washes with water, the plates
were air-dried and incubated overnight at 4◦C to enhance
spot clarity. Spots were counted using an automated ELISpot
reader (AID), and expressed as delta spot forming cells per 106
cells (SFC/106; SFC/106 of stimulated cells minus SFC/106 of
unstimulated control cells). The results were considered positive
if theSFC/106 wasmore than two standard deviations above the
mean of the control. Peptides were classed as positive epitopes if
two or more out of three, three or more out of four, or four or
more out of five immunized mice showed responses above this
value.
HLA Peptide Binding Assay
The relative binding affinity of LF peptides to HLA-DRmolecules
were determined by competitive ELISA, as previously described
(Texier et al., 2000). Briefly, affinity chromatography was
used to immunopurify HLA-DR molecules from homozygous
EBV-transformed lymphoblastoid B cell lines. The HLA-DR
molecules were diluted in binding buffer and incubated for
24–72 h with an appropriate biotinylated reporter peptide,
and a serial dilution of the competitor LF peptides. The
validity of each experiment was assessed by a control of
unlabeled reporter peptides. Binding neutralization buffer was
applied to the HLA-DR molecules and resultant supernatants
were incubated at room temperature in ELISA plates (Nunc,
Denmark) coated with monoclonal antibody L243. Bound
biotinylated peptide was detected by addition of streptavidin-
alkaline phosphatase conjugate (GE Healthcare, Saclay, France)
and 4-methylumbelliferyl phosphate substrate (Sigma–Aldrich,
France). A Gemini Spectramax Fluorimeter (Molecular Devices,
St. Gregoire, France) was used to measure fluorescence at
450 nm post-excitation at 365 nM. Sequences of the reference
peptide and their IC50 values were as follows: HA 306–
318 (PKYVKQNTLKLAT) for DRB1∗0101 (4 nM), DRB1∗0401
(8 nM), and DRB1∗1101 (7 nM), YKL (AAYAAAKAAALAA)
for DRB1∗0701 (3 nM), A3 152–166 (EAEQLRAYLDGTGVE)
for DRB1∗1501 (48 nM), MT 2–16 (AKTIAYDEEARRGLE) for
DRB1∗0301 (100 nM) and B1 21–36 (TERVRLVTRHIYNREE)
for DRB1∗1301 (37 nM). LF peptide concentration that
prevented binding of 50% of the labeled peptide (IC50) was
determined, and data was expressed as relative binding affinity
(ratio of IC50 of the LF competitor peptide to the IC50 of
the reference peptide which binds strongly to the HLA-DR
molecule). Strong binding affinity was defined as a relative
activity <10.
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FIGURE 1 | HLA transgenic mice immunized with LF peptide pools comprising domain III generate HLA-DR restricted CD4+ T cell cryptic epitopes.
Transgenic mice; DR1 (A,B), DR15 (C,D), and DR4 (E,F) were immunized with pools designed to only include non-overlapping LF peptides comprising domain III.
Draining lymph node cells were cultured in an IFNγ specific ELISpot plate with 25 μg/ml of the individual domain III LF peptides for 72 h. Results are given as the
number of spots above background (SFC)/106 PBMCs with mean ± SD (n = 3–5 mice for each column).
RESULTS
Immunization of HLA-DR Transgenic
Mice with Domain III Peptides Unveils
Cryptic Epitopes with an HLA Allele
Specific Focus
Cryptic epitopes have relevance to infectious disease as responses
to such epitopes may be unveiled as a consequence of antigen
processing differences during infection. Our own studies in
humans have demonstrated that environmental exposure to live
B. anthracis uncovers cryptic epitopes within LF, not identified
as T cell determinants following protein antigen vaccination
(Ingram et al., 2010). This raises the possibility that cryptic
epitopes may have a role in host-pathogen interplay in the
pathogenesis of anthrax in vivo.
Immunodominant T cell epitopes from LF are largely localized
to domains I, II and IV of LF. However, HLA binding
affinity studies suggested additional potential epitopes within
domain III not revealed by mapping the immunodominant
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FIGURE 2 | Immunodominant HLA-DR1 restricted T cell epitopes. HLA-DR1 transgenics were immunized with each of the immunodominant peptides
separately (A–L), and draining lymph node cells were cultured in an IFNγ specific ELISpot plate with the immunizing and flanking peptides or LF protein for 72 h.
Results are given as the number of spots above background (SFC)/106 PBMCs with mean ± SD (n = 4–5 mice for each column).
epitopes. Domain III was of specific interest due both to its
immunologically ‘silent’ nature, common to all HLA alleles
during immunodominant epitope mapping, and the role that
this region may play in dictating the stability and function of
the LF catalytic site. We therefore attempted to identify cryptic
CD4+ T cell responses to the peptides which encompass LF
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FIGURE 3 | Immunodominant HLA-DR15 restricted T cell epitopes. HLA-DR15 transgenics were immunized with each of the immunodominant peptides
separately (A–I), and draining lymph node cells were cultured in an IFNγ specific ELISpot plate with the immunizing and flanking peptides or LF protein for 72 h.
Results are given as the number of spots above background (SFC)/106 PBMCs with mean ± SD (n = 4–5 mice for each column).
domain III in mice transgenic for three common HLA-DR alleles
by immunizing with pools of non-overlapping LF peptides and
restimulating lymph node cells with the individual domain III
peptides.
A T cell recall response to the native protein as well as to
the individual peptides was only induced in mice immunized
with one peptide pool, HLA-DR1 transgenics demonstrated
a T cell recall response to peptides LF287−306, LF307−326,
LF327−346, LF347−366, and LF387−406 (Figure 1A), Only one
HLA-DR15 restricted cryptic epitope was identified; LF317−336
(Figure 1D), while the HLA-DR4 restricted cryptic epitopes were
identified as LF307−326 and LF387−406 (Figure 1E). Although,
in comparison to immunodominant epitopes, lower levels of
IFNγ were released from cells following stimulation with cryptic
epitopes, all positive epitopes were found to produce a SFC/106
more than two standard deviations above the negative control
mean value.
The largest number of LF domain III T cell epitopes were thus
detected in the context of HLA-DR1 presentation. The cryptic
epitopes LF307−326 and LF387−406 were common to both HLA-
DR1 and HLA-DR4 transgenics, although only presentation by
HLA-DR1 led to a recall response to the whole protein.
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FIGURE 4 | Immunodominant HLA-DR4 restricted T cell epitopes. HLA-DR4 transgenics were immunized with each of the immunodominant peptides
separately (A–G), and draining lymph node cells were cultured in an IFNγ specific ELISpot plate with the immunizing and flanking peptides or LF protein for 72 h.
Results are given as the number of spots above background (SFC)/106 PBMCs with mean ± SD (n = 3–4 mice for each column).
Single Peptide Immunization of
Immunodominant Epitopes Reveals
Peptides Capable of Inducing a
Response to the Native Protein
Different MHC class II alleles present largely different peptide
epitopes from a given antigen, shaping the T cell repertoire
activated in the immune response. This diversity was observed
here in the range of LF peptides presented by the HLA-
DR transgenics. In addition to allele specific epitopes, our
previous work reported that the domain II peptides LF457−476
and LF467−487, as well as the domain VI peptide LF547−568,
were all promiscuous immunodominant epitopes, capable of
eliciting a T cell response from all the HLA-DR transgenic
mice studied (Ascough et al., 2014b). The heteroclitic nature
of these peptides appears to be dependent upon the presenting
HLA-DR allele, as LF457−476 and LF467−487 were capable of
inducing a T cell response to the peptide, as well as to the
whole native LF protein in DR1 (Figures 2G,H) and DR15
(Figures 3B,C), but not in DR4 (Figures 4A,B) transgenics.
In contrast, the response to immunization with LF547−568 did
not lead to a response to the peptide within the context of
the whole protein, regardless of which HLA-DR allele was
presenting it.
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FIGURE 5 | HLA-DR4 transgenics immunized with LF peptide pools comprising domain I of the protein demonstrate CD4+ T cell cryptic epitopes.
HLA-DR4 transgenic mice were immunized with pools of non-overlapping LF peptides comprising domain I (A–D), and draining lymph node cells were cultured in an
IFNγ specific ELISpot plate with 25 μg/ml of each individual peptide from the immunizing pool. Results are given as the number of spots above background
(SFC)/106 PBMCs with mean ± SD (n = 5 mice for each column).
DR1 transgenics demonstrated T cell responses to a greater
number of domain III cryptic epitopes than other HLA-DR
transgenics, and we found that this pattern was repeated with
the immunodominant epitopes. Relative to other HLA-DR
transgenics the DR1 repertoire was found not only to consist
of a greater number of immunodominant epitopes, but also,
a greater proportion of these epitopes; LF171−190, LF457−476,
LF467−487, LF558−584, LF574−593, and LF674−693, induced a T
cell response when presented within the context of the whole
protein (Figure 2), compared to only four LF epitopes; LF457−476,
LF467−487, LF644−663, and LF714−733, in DR15 (Figure 3) and
none in DR4 transgenics (Figure 4).
Cryptic Domain I Peptides are Capable
of Inducing a Heteroclitic Response in
HLA-DR4 Transgenics
A feature of both the domain III cryptic epitopes (Figure 1)
and the immunodominant epitopes spread across domains II
and IV (Figure 4) in HLA-DR4 transgenics, was that they were
unable to induce a T cell response to the whole native LF protein.
To determine whether this was an inherent characteristic of
the HLA-DR4 restricted presentation of LF epitopes, we further
screened peptides from domain I, which does not contain any
immunodominant HLA-DR4 restricted epitopes, for the presence
of heteroclitic cryptic epitopes. This revealed the presence of
several unique epitopes, which had not been identified during
the mapping of immunodominant epitopes within this domain.
LF111−130, LF161−180, LF181−200, and LF221−240 all elicit T cell
responses following administration in peptide form (Figure 5).
Furthermore, the peptide pool which contained LF111−130
was also found to be capable of inducing a response which
encompassed the whole native LF protein.
These results suggest that the cryptic and immunodominant
epitopes within the LF protein are influenced to a great extent by
the allele of the HLA class II molecules responsible for peptide
presentation.
HLA Class II Binding of Cryptic Epitopes
Across Distinct HLA-DR Polymorphisms
The overlapping 20-mers representing domains III (Table 1)
and I (Table 2) of LF were evaluated for binding to seven
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TABLE 1 | HLA restricted cryptic epitopes identified within domain III with relative binding affinity.
LF peptide sequence HLA-restriction Relative binding affinity of peptide to HLA-DR molecules
DR1 DR3 DR4 DR7 DR11 DR13 DR15
287 LSLEELKDQRMLSRYEKWEK 306 DR1 31 3 >1250 1,414 17 3 18
307 IKQHYQHWSDSLSEEGRGLL 326 DR1, DR4 73 900 2 53 84 857 67
317 SLSEEGRGLLKKLQIPIEPK 336 DR15 149 >667 >1788 488 23 100 268
327 KKLQIPIEPKKDDIIHSLSQ 346 DR1 0.2 2 750 1,195 1,200 857 14
347 EEKELLKRIQIDSSDFLSTE 366 DR1 267 0.4 9 120 9 926 0.2
387 KELLNRIQVDSSNPLSEKEK406 DR1, DR4 146 1 0 36 274 1,714 1
The relative binding affinity of peptides to HLA-DR molecules were expressed as a relative activity (ratio of the IC50 of the peptide to the IC50 of a reference peptide which
binds strongly to the individual HLA II molecule). Peptides with a high relative binding affinity of <10 are indicated in bold, while moderate binding is characterized by a
range of relative affinity varying from 10 to 100. Means were calculated from at least three independent measurements.
TABLE 2 | HLA-DR4 restricted cryptic epitopes identified within domain I with relative binding affinity.
LF peptide sequence Relative binding affinity of peptide to HLA-DR molecules
DR1 DR3 DR4 DR7 DR11 DR13 DR15
111 GGKIYIVDGDITKHISLEAL 130 122 >1000 61 15 75 21 6
161 VLVIQSSEDYVENTEKALNV 180 1702 82 29 66 168 >172 958
181 YYEIGKILSRDILSKINQPY 200 69 3 19 4 0.4 5 43
221 LLFTNQLKEHPTDFSVEFLE 240 909 >76 6 51 148 >172 193
The relative binding affinity of peptides to HLA-DR molecules were expressed as a relative activity (ratio of the IC50 of the peptide to the IC50 of a reference peptide which
binds strongly to the individual HLA II molecule). Peptides with a high relative binding affinity of <10 are indicated in bold, while moderate binding is characterized by a
range of relative affinity varying from 10 to 100. Means were calculated from at least three independent measurements.
common HLA-DR alleles, DRB1∗0101 (DR1), DRB1∗0401
(DR4), DRB1∗1101 (DR11), DRB1∗0701 (DR7), DRB1∗1501
(DR15), DRB1∗0301 (DR3) and DRB1∗1301 (DR13).
Within domain III (Table 1) the DR1 restricted epitopes
LF287−306 and LF327−346 showed moderate and strong binding
to HLA-DR1, respectively. LF307−326 and LF387−406, which were
identified in the DR4 and DR1 transgenics, both showed strong
binding to HLA-DR4, but only LF307−326 showed moderate
binding to HLA-DR1. All of the DR4-restricted domain I cryptic
epitopes (Table 2) identified in the transgenics showed a strong
to moderate relative binding affinity to HLA-DR4 molecules
of <100, with LF221−240 demonstrating the highest binding
affinity. Whilst the LF181−200 peptide exhibited promiscuous
binding of <100 to all the HLA-DRmolecules assayed. However,
none of the cryptic epitopes from either domain III or I
displayed notably high binding affinities across all HLA-DR
alleles assayed
DISCUSSION
Microbial antigen presentation through HLA class II is a
crucial step in initiating adaptive immunity to infection,
the considerable allelic diversity of these class II molecules
influencing susceptibility to infection. HLA class II transgenic
mice were here used to characterize HLA restricted T cell
responses to immunogenic epitopes of the LF toxin secreted
by B. anthracis. The value of such studies is that they offer
reductionist tools for mapping the microbial epitopes likely to
be presented to T cells in humans carrying the same HLA
alleles.
Themajor variables that influence the immunodominance and
crypticity of epitopes derived from an antigen such as LF, remain
a focus of speculation. It has been suggested that intrinsic features
within the protein molecule reduce the availability of particular
epitopes, and efficient endosomal antigen processing may be
hampered by flanking amino acids which either promote the
enzymatic destruction of the determinant or hinder processing
through slow or incomplete unfolding of the protein molecule
(Moudgil et al., 1998;Musson et al., 2003, 2006). This is supported
by studies indicating that immunodominant epitopes tend to
cluster within regions which are either within or adjacent to
protease-sensitive loops (Carmicle et al., 2007). The non-classical
MHC class II heterodimer DM has also been implicated in
directing the cryptic and immunodominant fate of epitopes,
although it remains unclear whether this is due to the DM
induced editing of the epitope repertoire to favor peptides which
display a higher binding affinity for MHCmolecules (Kropshofer
et al., 1996; Nanda and Sant, 2000; Nanda and Bikoff, 2005).
The critical role peptide binding plays in determining dominance
hierarchies has also been demonstrated by studies showing a
direct correlation between immunodominance and the binding
affinities of the MHC/peptide complex (Lazarski et al., 2005;
Weaver et al., 2008). We discovered that although a number
of epitopes such as the HLA-DR4 restricted LF307−326 and
LF387−406, showed a strong binding affinity to the relevant MHC
class II molecule, the strength of HLA binding did not adequately
predict the immunodominance or crypticity of LF peptides. The
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underlying mechanisms governing the epitope hierarchy as yet
remain unclear, however, our results indicate that identifying
cryptic as well as immunodominant epitopes located within the
anthrax toxins may be relevant in the attempt to elicit protective
immune responses toward B. anthracis.
Immunization with cryptic or subdominant determinants has
been found to contribute to an broadened T cell repertoire
which provides increased protection against infection, compared
to immunization with a single immunodominant epitope
(Dominguez et al., 2011). By exploring the subdominant or
cryptic responses to domain III and domain I within the context
of HLA transgenics, we were able to identify cryptic epitopes
which could be incorporated into polyepitopic vaccines alongside
immunodominant T cell epitopes. This is particularly pertinant
to anthrax infection, as previous studies have established that
the T cell repertoire following immunization and live anthrax
infection differs in regard to the epitopes uncovered (Ingram
et al., 2010). The possibility that infection works to skew
the epitopes which are preferentially processed or presented,
uncovering infection specific epitopes, raises the possibility that
epitopes which are not immunodominant, but rather cryptic or
subdominant, may be relevant to the design of epitope string
vaccines.
Furthermore, immunization with peptides which elicit a
T cell response to the peptide in the context of the whole
protein has been correlated with survival following pathogen
infection (Zhang et al., 2009); within our study cryptic and
immunodominant epitopes capable of eliciting a strong T cell
response following administration in peptide form alone, were
identified. The epitope pool which contained the DR1-restricted
cryptic domain III epitopes LF287−306, LF307−326, LF327−346,
LF347−366, and LF387−406 and the pool containing the DR4-
restricted cryptic domain I epitope LF111−130, were the only
cryptic epitopes identified capable of inducing a response to
the whole protein. In contrast, a number of immunodominant
epitopes, both HLA-DR1 and DR15 restricted, were identified
which were capable of inducing a response to the whole LF
protein. This included LF457−476 and LF467−487, which, unlike
the majority of epitopes which are unique to a particular HLA
allele, were a feature of both DR1, DR15, and DR4 transgenic
responses. Although it should be noted that these promiscuous
epitopes were unable to provoke a response to the peptides
within the context of the whole protein following presentation
by HLA-DR4. In fact, only cryptic epitopes from domains I
and III were found to lead to a heteroclitic response against
the whole protein in DR4 transgenics, this suggests not only
that regions which appear devoid of immunodominant epitopes
may instead contain cryptic or subdominant epitopes, but also
that the epitopes presented are influenced to a great extent by
the nature of the MHC class II molecules. The HLA class II
molecules are among the most polymorphic glycoproteins known
in nature (Robinson et al., 2015). They play a crucial role in
restricting the number of potential epitopes generated following
the intracellular processing of antigens. MHC polymorphism
is concentrated in the region encoding the peptide-binding
groove, giving rise to a largely distinct set of epitopes that bind
in a preferential manner to each distinct HLA allele. Murine
studies have identified epitopes whose dominance or crypticity
was dependent on the H-2 haplotype involved in presentation
(Grewal et al., 1995; Moudgil et al., 1998; Sinha et al., 2007).
It is therefore plausible that whilst none of the cryptic epitopes
displayed a discernable pattern of binding across the HLA-DR
alleles assayed, the different patterns of peptide binding affinity
displayed by these LF epitopes, and specifically their ability to
induce responses within the context of the whole LF protein,
reflect the requirements of each MHC peptide binding cleft,
which are nevertheless capable of inducing high avidity T cell
responses.
The CD4+ T cell response across the distinct HLA alleles
described in our results indicates that the immunodominant
LF epitopes are overwhelmingly concentrated in domains II
and IV, whilst domains I and III contain a small number of
cryptic epitopes, presented in an HLA dependent manner. This
contrasts with previous studies identifying B cell epitopes within
the LF protein, which found that the levels of toxin neutralizing
antibodies, proven to correlate with protection against lethal
spore challenge (Baillie et al., 2008), are induced by domain
I and II immunization. Domain III has also been found to
be rich in binding sites for toxin neutralizing antibodies (Lim
et al., 2005; Albrecht et al., 2007; Nguyen et al., 2009b). Indeed,
the work by Nguyen et al. (2009a) indicated that domain III
contained a number of structural B cell epitopes, making it
extremely antigenic within this context. These results may reflect
the nature of the conformational epitopes which, unlike linear
CD4+ T cell epitopes, can be lost when domains are expressed
as individual recombinant proteins. As CD4+ T cells play a
crucial role in directing the adaptive immune response, not only
through promoting the expansion of cytotoxic CD8+ T cells and
maintaining the memory T cell population, but also through
promoting B cell differentiation into plasma cells to produce
neutralizing antibodies and assist memory B cells for a swift
recall response. The identification of cryptic CD4+ T cell epitopes
which may also be involved in initiating a neutralizing antibody
response against LF would allow both the humoral and cellular
immune system to provide robust protection to anthrax infection
following immunization.
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